Takeda said its oral TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 trial for plaque psoriasis. Takeda reported statistical superiority across primary and secondary endpoints, including complete skin lesion clearance in a higher proportion of patients at 16 weeks. The result extends Takeda’s momentum in a competitive oral-inflammation field where efficacy—measured against injectable comparators—has been a key differentiator. The company did not disclose detailed figures in the provided materials, but positioned the data as supportive of a future oral entry into plaque psoriasis treatment.